A question has thus arisen: Can we block FSH action to achieve a therapeutic benefit for osteoporosis, obesity, and AD — simultaneously — particularly in menopausal women? This evidence concerns the gene BRD2 and obesity due to melanocortin 4 receptor deficiency.